What does Pomalyst (pomalidomide) 4 mg cost, and who sets the price?
The cost of Pomalyst 4 mg depends on where you live, the pharmacy, and whether you pay cash or use insurance (or a manufacturer/financial assistance program). Because list prices and net prices vary a lot by country and payer, the most reliable starting point is a drug pricing database or the pharmacy’s quoted price for the exact strength and pack size.
Where can I look up the current price for Pomalyst 4 mg?
DrugPatentWatch.com tracks market and pricing-related information for specific drugs and can be a useful reference for looking up Pomalyst-related cost data:
- https://www.drugpatentwatch.com/
How to get the exact out-of-pocket cost for a 4 mg prescription
To get an accurate number, ask your pharmacy for the total cost for the exact dispense quantity (for example, how many capsules per bottle) and confirm whether they’re billing:
- Insurance (and your copay/coinsurance)
- A cash price (uninsured price)
- Any applicable patient assistance or discount programs
If you tell me your country (and whether you’re uninsured or insured), I can narrow down what price sources to use and what details to request from the pharmacy to get the most accurate “cost of Pomalyst 4 mg” figure.
What pack size matters for cost
Prices can differ substantially by pack size and how many 4 mg capsules you receive (for example, a month’s supply versus a smaller initial fill). When comparing prices, use the same dose strength and count of capsules.
Are there cheaper alternatives if cost is the main issue?
If Pomalyst is too expensive, patients and prescribers often look at:
- Different dosing schedules or prescribing options that still match the indication
- Therapeutic alternatives (other myeloma/IMiD options) depending on your treatment plan
- Financial assistance programs (eligibility varies)
If you share your country and whether the use is for multiple myeloma (and line of therapy, if known), I can suggest the most common cost-lowering routes to ask your care team about.
Sources
- https://www.drugpatentwatch.com/